Retrieve Medical (RMHI) 10-Q 13 Aug 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	9 Months Ended
	Jun. 30, 2015	Aug. 11, 2015	Mar. 31, 2014
Document and Entity Information:
Entity Registrant Name	PEAK PHARMACEUTICALS, INC.
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Entity Central Index Key	1,452,804
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		78,363,562
Entity Public Float			$ 0
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Current Assets
Cash	$ 239,621	$ 451,431
Inventory	95,550
Prepaid Expenses	37,724	6,838
Total Current Assets	372,895	458,269
Fixed assets, net of depreciation	1,701
Intangible Asset, Net of Amortization	21,227	30,139
Deposit	10,334	2,500
Total Assets	406,157	490,908
Current Liabilities
Accounts Payable	219,097	43,534
Account Payable - Related Parties	34,487	10,893
Accounts Payable Insurance	23,774
Accrued Liabilities	52,777
Total Current Liabilities	330,133	54,427
Total Liabilities	330,133	54,427
Stockholders' Equity
Common stock	7,836	7,816
Additional Paid-in Capital	5,821,022	4,287,720
Accumulated Deficit	$ (5,752,834)	$ (3,859,055)
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	325,000,000	325,000,000
Common stock, shares issued	78,363,562	78,163,562
Common stock, shares outstanding	78,363,562	78,163,562
Total Stockholders' Equity (Deficit)	$ 76,024	$ 436,481
Total Liabilities and Stockholders' Equity (Deficit)	$ 406,157	$ 490,908

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Cost of Revenue	$ 317,244		$ 751,313
Gross Profit	138,432		310,471
Total Revenue	178,812		440,842
Expenses
General and Administrative	633,852	$ 961,765	2,334,728	$ 1,406,287
Depreciation and Amortization	3,443	2,085	9,398	2,085
Cost Associated with Exploring Business Opportunity				412,144
Total Operating Expenses	667,295	963,850	2,334,126	1,820,486
Loss From Operations	(488,483)	(963,850)	(1,893,284)	(1,820,486)
Other Income (Expense)
Interest Expense		(666,240)	(495)	(696,628)
Gain on Extinguishment of Debt				24,650
Total Other Income (Expense)		(666,240)	(495)	(671,978)
Net (Loss)	$ (488,483)	$ (1,630,090)	$ (1,893,779)	$ (2,492,464)
Basic and Diluted (Loss) per Common Share	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.03)
Weighted Average Number of Common Shares Outstanding	78,363,562	72,532,768	78,305,591	76,330,189

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities:
Net Cash Used in Operating Activities	$ (209,632)	$ (721,971)
Cash Flows From Investing Activities:
Purchase of Fixed Assets	(2,187)
Investment in website		(35,000)
Net Cash Used in Investing Activities	(2,187)	(35,000)
Cash Flows From Financing Activities:
Proceeds from Debt		500,000
Sale of Stock		940,000
Repurchase of Stock		(125,000)
Net Cash Provided by Financing Activities		1,315,000
Increase (Decrease) in Cash	(211,810)	558,029
Initial Cash	451,431	4,906
Final Cash	239,621	562,935
Supplemental Disclosures
Cash Paid for Interest	$ 495
Non-cash Financing Activities:
Common Shares for Settlement of Debt		9,860
Conversion of Debt Into Common Shares		649,780
Shares Cancelled		$ 30,000

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Notes
Note 1 - Summary of Significant Accounting Policies	Note 1 – Summary of Significant Accounting Policies Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its subsidiary. The accompanying unaudited condensed consolidated financial statements of Peak Pharmaceuticals, Inc., at June 30, 2015 and 2014 have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2014. In management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the periods ended June 30, 2015 and 2014 presented are not necessarily indicative of the results to be expected for the full year. Peak Pharmaceuticals, Inc. was incorporated in Nevada on December 18, 2007 as Surf A Movie Solutions Inc., which was previously engaged in the development, sales and marketing of online video stores. We decided to change our business objective and in connection therewith we first changed our name to Frac Water Systems, Inc. and explored the possibilities of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities. On December 31, 2013, we determined not to move forward with that business model. On March 14, 2014, we changed our name to Cannabis Technology Corp. The name change was made in connection with our entry into the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases. On December 23, 2014, we changed our name again to Peak Pharmaceuticals, Inc. This name change was made to make our name more consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. Financial statements prepared in conformity with GAAP contemplate a company’s continuation as a going concern. We have incurred net losses since inception. In addition, we have an accumulated deficit of $5,752,834 as of June 30, 2015. This condition raises substantial doubt as to our ability to continue as a going concern. In response to these conditions, we may raise additional capital through the sale of equity securities, through an offering of debt securities or through borrowings from financial institutions or individuals. These financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Reclassification Certain amounts from prior quarters have been reclassified for consistency with the presentation of the three months and nine months ended June 30, 2015. These reclassifications had no effect on the reported results of operations. Basis of Consolidation The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation. Inventory Inventory consists of finished goods and is carried at the lower of cost or market on a first in first out basis. Revenue Recognition We recognize revenue from products sold when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable and collection is reasonably assured. Revenue represents the sale of products and related shipping fees. Cost of Revenue Cost of revenue includes the cost of products sold and shipping costs attributable to the revenue. Expenses associated with exploring business opportunities Through the period ended March 31, 2014, we were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of certain notes and other payments under the Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the assumption of debt related to the Agreement and $2,413 which is the fair value of options granted under the Agreement. Research and Development Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $276 and $12,143 in research and development expenses for the three and nine months ended June 30, 2015, respectively. There were no research and development expenses in 2014. Loss per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share Recent Pronouncements From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly.

Note 2 - Intangibles

Note 2 - Intangibles	9 Months Ended
	Jun. 30, 2015
Notes
Note 2 - Intangibles	Note 2 - Intangibles Intangibles at June 30, 2015 and September 30, 2014, consist of Website, $35,000, less accumulated amortization of $13,773 and $4,861, respectively. The website is being amortized over three years. Estimated future amortization expense related to intangible property as of June 30, 2015 is as follows: Years ending September 30, Total Amortization 2015 $ 2,917 2016 11,667 2017 6,643 $ 21,227

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	9 Months Ended
	Jun. 30, 2015
Notes
Note 3 - Related Party Transactions	Note 3 – Related Party Transactions Parties, which can be corporations or individuals, are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence. Accounts payable – related parties are the amounts payable to officers and directors of the Company for reimbursement of expenses they incurred on behalf of the Company as well as Director fees.

Note 4 - Commitments and Contin

Note 4 - Commitments and Contingencies	9 Months Ended
	Jun. 30, 2015
Notes
Note 4 - Commitments and Contingencies	Note 4 – Commitments and Contingencies Canna-Pet License Agreement In July, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with a Washington limited liability corporation (“Licensor”), which owns the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”), used by Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp which are intended exclusively for consumption by pets. Pursuant to the License Agreement, Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gives us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provides us with an immediate revenue source and access to Licensor’s customer base. During the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor. In consideration of the grant of the license, we have agreed to pay Licensor license fees in the form of royalty payments calculated on the basis of gross proceeds received by us from sales of products manufactured, marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor. The royalty will be calculated and paid by us on a quarterly basis using calendar quarters ending March 31, June 30, September 30, and December 31 each year and will be equal to fifteen percent (15%) of the first $1,000,000 of gross proceeds received by us during the quarter and ten percent (10%) on gross proceeds in excess of $1,000,000 received by us during the quarter. On or before the date, which is 45 days following the end of each calendar quarter, we will calculate the amount of the royalty due to Licensor for that quarter and will make payment in full of such amount to Licensor. For purposes of calculating the amount of royalty due for each quarter, “gross proceeds” will not include amounts received by us as payments for any and all taxes, duties, governmental charges, sales expenses, freight or shipping charges, and the like. Commencing in 2015, we have agreed to pay Licensor a guaranteed minimum royalty amounts based upon the gross proceeds received by us from the sale of products (the “License Based Products”) utilizing the Licensed Intellectual Property or subsequently developed jointly owned intellectual property. The guaranteed minimum royalty payments are as follows: Time Period Minimum Annual License Fee January 1, 2015 through December 31, 2015 Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000. January 1, 2016 through December 31, 2016 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2017 through December 31, 2017 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2018 through December 31, 2018 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2019 through December 31, 2019 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2020 through December 31, 2020, and all succeeding years The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019. All royalty payments made by us during any calendar year will be credited against the minimum annual royalty amounts due and payable by us for such year. In the event that the aggregate amount of royalties payable by us for any calendar year are not sufficient to satisfy our minimum annual royalty payment obligation for that year, we will be obligated to pay the unpaid balance of the minimum royalty amount to Licensor on or before February 28 of the following year Royalty expense for the three and nine month periods ended June 30, 2015 were $42,805 and $100,149, respectively, and are included in general and administrative expenses and accrued liabilities. Non-cancelable Operating Lease We lease office and lab space under non-cancelable operating lease, which expires August 31, 2015. There are no automatic extension periods in the lease. The aggregate minimum requirements under non-cancelable leases as of June 30, 2015 are as follows: Years ending September 30, 2015 $ 5,820 Rent expense was $5,820 and $190 for the three months ended June 30, 2015 and 2014, respectively, and $17,971 and $4,190 for the nine months ended June 30, 2015 and 2014, respectively. Accounts payable insurance relates to committed payments for the purchase of insurance. The amount of the insurance policy was $60,000 and the original payable was $48,000, bears interest at the rate of 6.5% per annum, and has monthly payments of $4,944 through September, 2015.

Note 5 - Stockholders' Equity

Note 5 - Stockholders' Equity	9 Months Ended
	Jun. 30, 2015
Notes
Note 5 - Stockholders' Equity	Note 5 – Stockholders’ Equity On December 22, 2014, pursuant to a Placement Agent Agreement, we issued 200,000 restricted shares of our common stock. The shares were valued at $36,000 $0.18 per share, the trading value, and charged to stock based compensation.

Note 6 - Options

Note 6 - Options	9 Months Ended
	Jun. 30, 2015
Notes
Note 6 - Options	Note 6 – Options In 2013 we issued options The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $2,413. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 130 % Risk Free interest rate 2.71 % Dividend yield (on common stock) - In May 2014, we issued non-qualified options to purchase 4,500,000 shares of our common stock to certain officers of the Company. The options are exercisable at $0.20 per share and have graded vesting over 4 years. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $4,415,649. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 123 % Risk Free interest rate 2.56 % Dividend yield (on common stock) - As per guidance in the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), we are amortizing the fair value of the options on a straight line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards (graded vesting attribution method). The following is a summary of outstanding stock options issued to employees and directors as of June 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding September 30, 2014 7,416,000 $ 0.0067 -0.20 - $ - Issued - $ - - - Cancelled - $ - - - Outstanding June 30, 2015 7,416,000 $ 0.0067 - 0.20 8.82 $ - Exercisable 4,116,000 $ 0.0067 - 0.20 8.76 $ - The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of June 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding September 30, 2014 375,000 $ 0.0067 - $ - Issued - $ - Cancelled - $ - - Outstanding June 30, 2015 375,000 $ 0.0067 8.3 $ - Exercisable 375,000 $ 0.0067 8.3 $ - Total option expense for the three and nine months ended June 30, 2015 was $400,581 and $1,497,322, respectively.

Note 7 - Income Tax

Note 7 - Income Tax	9 Months Ended
	Jun. 30, 2015
Notes
Note 7 - Income Tax	Note 7 – Income Tax We account for income taxes in interim periods in accordance with ASC Topic 740, Income Taxes (“ASC 740”). We have determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during our fiscal year to our best current estimate. As of June 30, 2015 the estimated effective tax rate for the year will be zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit our tax returns from 2011 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statement of operations. There have been no income tax related interest or penalties assessed or recorded. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This pronouncement also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. For the three and nine months ended June 30, 2015 and 2014 we did not have any interest and penalties associated with tax positions. As of June 30, 2015 we did not have any significant unrecognized uncertain tax positions.

Note 8 - Subsequent Events

Note 8 - Subsequent Events	9 Months Ended
	Jun. 30, 2015
Notes
Note 8 - Subsequent Events	Note 8 – Subsequent Events Management has evaluated all activity and concluded that no subsequent events have occurred that would require recognition in these financial statements or disclosure in the notes to these financial statements.

Note 1 - Summary of Significa13

Note 1 - Summary of Significant Accounting Policies: Reclassification (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Reclassification	Reclassification Certain amounts from prior quarters have been reclassified for consistency with the presentation of the three months and nine months ended June 30, 2015. These reclassifications had no effect on the reported results of operations.

Note 1 - Summary of Significa14

Note 1 - Summary of Significant Accounting Policies: Basis of Consolidation (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.

Note 1 - Summary of Significa15

Note 1 - Summary of Significant Accounting Policies: Inventory (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Inventory	Inventory Inventory consists of finished goods and is carried at the lower of cost or market on a first in first out basis.

Note 1 - Summary of Significa16

Note 1 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Revenue Recognition	Revenue Recognition We recognize revenue from products sold when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable and collection is reasonably assured. Revenue represents the sale of products and related shipping fees. Cost of Revenue Cost of revenue includes the cost of products sold and shipping costs attributable to the revenue.

Note 1 - Summary of Significa17

Note 1 - Summary of Significant Accounting Policies: Research and Development (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Research and Development	Expenses associated with exploring business opportunities Through the period ended March 31, 2014, we were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of certain notes and other payments under the Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the assumption of debt related to the Agreement and $2,413 which is the fair value of options granted under the Agreement. Research and Development Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $276 and $12,143 in research and development expenses for the three and nine months ended June 30, 2015, respectively. There were no research and development expenses in 2014.

Note 1 - Summary of Significa18

Note 1 - Summary of Significant Accounting Policies: Loss Per Share (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Loss Per Share	Loss per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share

Note 1 - Summary of Significa19

Note 1 - Summary of Significant Accounting Policies: Recent Pronouncements (Policies)	9 Months Ended
	Jun. 30, 2015
Policies
Recent Pronouncements	Recent Pronouncements From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly.

Note 2 - Intangibles_ Schedule

Note 2 - Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables)	9 Months Ended
	Jun. 30, 2015
Tables/Schedules
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Years ending September 30, Total Amortization 2015 $ 2,917 2016 11,667 2017 6,643 $ 21,227

Note 4 - Commitments and Cont21

Note 4 - Commitments and Contingencies: Guaranteed Minimum Royalty Payments (Tables)	9 Months Ended
	Jun. 30, 2015
Tables/Schedules
Guaranteed Minimum Royalty Payments	Time Period Minimum Annual License Fee January 1, 2015 through December 31, 2015 Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000. January 1, 2016 through December 31, 2016 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2017 through December 31, 2017 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2018 through December 31, 2018 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2019 through December 31, 2019 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2020 through December 31, 2020, and all succeeding years The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019.

Note 6 - Options_ Schedule of S

Note 6 - Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables)	9 Months Ended
	Jun. 30, 2015
Options
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 130 % Risk Free interest rate 2.71 % Dividend yield (on common stock) -
Non-Qualified Options
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 123 % Risk Free interest rate 2.56 % Dividend yield (on common stock) -

Note 6 - Options_ Schedule of23

Note 6 - Options: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	9 Months Ended
	Jun. 30, 2015
Employee
Schedule of Share-based Compensation, Stock Options, Activity	Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding September 30, 2014 7,416,000 $ 0.0067 -0.20 - $ - Issued - $ - - - Cancelled - $ - - - Outstanding June 30, 2015 7,416,000 $ 0.0067 - 0.20 8.82 $ - Exercisable 4,116,000 $ 0.0067 - 0.20 8.76 $ -
Non-Employee
Schedule of Share-based Compensation, Stock Options, Activity	Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding September 30, 2014 375,000 $ 0.0067 - $ - Issued - $ - Cancelled - $ - - Outstanding June 30, 2015 375,000 $ 0.0067 8.3 $ - Exercisable 375,000 $ 0.0067 8.3 $ -

Note 1 - Summary of Significa24

Note 1 - Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Details
Accumulated Deficit	$ (5,752,834)	$ (3,859,055)

Note 1 - Summary of Significa25

Note 1 - Summary of Significant Accounting Policies: Research and Development (Details) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Mar. 31, 2014	Jun. 30, 2015
Details
Noncash or Part Noncash Acquisition, Debt Assumed		$ 102,932
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 2,413
Research and Development Expense	$ 276		$ 12,143

Note 2 - Intangibles (Details)

Note 2 - Intangibles (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Details
Website Development Cost	$ 35,000	$ 35,000
Amortization of Website	$ 13,773	$ 4,861

Note 2 - Intangibles_ Schedul27

Note 2 - Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Details
Estimated Future Amortization Expense 2015	$ 2,917
Estimated Future Amortization Expense 2016	11,667
Estimated Future Amortization Expense 2017	6,643
Intangible Asset, Net of Amortization	$ 21,227	$ 30,139

Note 4 - Commitments and Cont28

Note 4 - Commitments and Contingencies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Details
Direct Operating Cost, Royalty Expense	$ 42,805		$ 100,149
Operating Leases, Future Minimum Payments Due	5,820		5,820
Operating Leases, Rent Expense, Net	$ 5,820	$ 190	$ 17,971	$ 4,190
Accounts Payable, Underwriters, Promoters, and Employees (Other than Salaries and Wages), Current					$ 60,000
Accounts Payable, Interest-bearing, Interest Rate					6.50%

Note 5 - Stockholders' Equity (

Note 5 - Stockholders' Equity (Details) - Dec. 31, 2014 - USD ($)	Total
Details
Stock Issued During Period, Shares, Restricted Stock Award, Gross	200,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 36,000
Share Price	$ 0.18

Note 6 - Options (Details)

Note 6 - Options (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2014
Option Expense	$ 400,581	$ 1,497,322
Options
Fair Value of Options			$ 2,413
Non-Qualified Options
Fair Value of Options			$ 4,415,649

Note 6 - Options_ Schedule of31

Note 6 - Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - 12 months ended Sep. 30, 2014	Total
Options
Expected Life	10 years
Volatility	130.00%
Risk Free Interest Rate	2.71%
Non-Qualified Options
Expected Life	10 years
Volatility	123.00%
Risk Free Interest Rate	2.56%

Note 6 - Options_ Schedule of32

Note 6 - Options: Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Employee
Options Outstanding	7,416,000	7,416,000
Exercise Price Lower Limit - Options Outstanding	$ 0.0067	$ 0.0067
Exercise Price Upper Limit - Options Outstanding	$ 0.20	$ 0.20
Average Remaining Term in Years - Options Outstanding	8 years 9 months 25 days
Options Exercisable	4,116,000
Exercise Price - Options Exercisable	$ 0.20
Remaining Term in Years - Options Exercisable	8 years 9 months 4 days
Non-Employee
Options Outstanding	375,000	375,000
Average Remaining Term in Years - Options Outstanding	8 years 3 months 18 days
Options Exercisable	375,000
Exercise Price - Options Exercisable	$ 0.0067
Remaining Term in Years - Options Exercisable	8 years 3 months 18 days
Exercise Price	$ 0.0067	$ 0.0067